Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Clinical Trials Commercial Research & Development

LIB Therapeutics Has An Unorthodox Funding Method And Big Plans

  • Interviews

Executive Summary

Armed with highly satisfactory Phase III cholesterol-lowering data, the private group is heading to market alone – though it is open to offers. 

You may also be interested in...



Asia Deal Watch: US Biotech LIB Partners In Greater China With Hasten On PCSK9 Therapy

Plus deals involving Astellas/Menarini, Maruho/Fortress Biotech, Zenas/Bristol Myers Squibb, Huadong Medicine/MC2 and more.

A Look Into The Future Of NASH

The liver disease is one of the hottest areas of drug development. Here are some upcoming catalysts to look out for.

Taking On Obesity The Hard Way

Despite the astounding efficacy and commercial potential of incretins in obesity, many groups are trying different mechanistic approaches to the disease – if only to enable combinations. 

Table

View full table

Topics

Related Companies

Tags:
Clinical Trials Commercial Research & Development
Latest Headlines

Glenmark Divests API Company, Setting Out On Distinct Journeys

Infographic: A Snapshot Of Non-Alcoholic Steatohepatitis R&D

A Look Into The Future Of NASH

Travere Hopes For FDA Full Approval Despite Filspari Trial Endpoint Miss

See All
UsernamePublicRestriction

Register

SC148978

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By